CHIKV VLP/adjuvant + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chikungunya Virus

Conditions

Chikungunya Virus

Trial Timeline

May 12, 2022 → Aug 8, 2023

NCT ID

NCT05349617

About CHIKV VLP/adjuvant + Placebo

CHIKV VLP/adjuvant + Placebo is a phase 3 stage product being developed by Bavarian Nordic for Chikungunya Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT05349617. Target conditions include Chikungunya Virus.

What happened to similar drugs?

0 of 10 similar drugs in Chikungunya Virus were approved

Approved (0) Terminated (2) Active (8)

🔄CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3

🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3

🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3

❌VLA1553Valneva SEPhase 3

🔄Biological Vaccine VLA1553Valneva SEPhase 3

🔄Active + PlaceboValneva SEPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05349617	Phase 3	Completed	May 12, 2022	Aug 8, 2023	Chikungunya Virus
NCT05072080	Phase 3	Completed	Sep 29, 2021	Apr 3, 2023	Chikungunya Virus

Competing Products

20 competing products in Chikungunya Virus

See all competitors

Product	Company	Stage	Hype Score
VAL-181388	Moderna	Phase 1	0
mRNA-1944	Moderna	Phase 1	0
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo	Bavarian Nordic	Phase 2	32
Chikungunya	Bavarian Nordic	Phase 2	32
CHIKV VLP vaccine booster + Placebo booster	Bavarian Nordic	Phase 3	41
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	37
CHIKV VLP, adjuvanted	Bavarian Nordic	Phase 2	32
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	44
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	44
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	27
VLA1553	Valneva SE	Phase 3	26
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	24
Biological Vaccine VLA1553	Valneva SE	Phase 3	34
VLA1553 full dose + VLA1553 half dose + Control	Valneva SE	Phase 2	29
Active + Placebo	Valneva SE	Phase 3	34
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH	Valneva SE	Pre-clinical	27
VLA1553	Valneva SE	Phase 3	38
VLA1553 + Control	Valneva SE	Phase 3	26
VLA1553 + Placebo	Valneva SE	Phase 3	34
VLA1553	Valneva SE	Phase 1	23